PetCaseFinder

Peer-reviewed veterinary case report

Amlodipine lowers kidney disease marker SDMA in dogs

By Morita, Shohei et al.·Published in Frontiers in veterinary science·2025·Tokyo University of Agriculture and Technology, Japan·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Amlodipine improves symmetric dimethylarginine in dogs with chronic kidney disease.

Species:
dog

Plain-English summary

A group of dogs with chronic kidney disease (CKD) were treated with amlodipine, a medication commonly used to lower high blood pressure. After starting the treatment, the dogs showed a significant decrease in their symmetric dimethylarginine (SDMA) levels, which is a marker for kidney function. This improvement was noted in both dogs with high blood pressure and those without. Additionally, the dogs' blood pressure decreased, and their heart function improved. Overall, amlodipine was found to be effective and safe for improving kidney function in dogs with CKD, regardless of their blood pressure status.

People also search for: dog chronic kidney disease treatment · amlodipine for dogs · dog kidney function improvement · high blood pressure in dogs · SDMA levels in dogs

Abstract

INTRODUCTION: In canines, chronic kidney disease (CKD) is frequently associated with high blood pressure. Amlodipine is used to treat hypertension in dogs, and we anticipated that amlodipine administration might improve renal function in dogs. However, the effect of amlodipine on canine renal function is unknown. Therefore, this study evaluated changes in symmetric dimethylarginine (SDMA) levels before and after amlodipine administration in pet dogs that had been diagnosed with CKD based on persistently elevated SDMA levels and were being treated with amlodipine alone for any reason. We also conducted a comparative investigation of whether there were any differences in SDMA changes depending on whether these dogs with CKD had hypertension. METHODS: This study employed a retrospective design. The study subjects were pet dogs that exhibited persistently elevated SDMA (&#x2265;14 &#x3bc;g/dL), were diagnosed with CKD, and were treated with amlodipine. Profile data such as breed, sex, and age, as well as data on blood chemistry tests, blood pressure, heart rate, and echocardiograms before and after amlodipine administration, were collected. Forty-five dogs were included in the study, of which 20 were hypertensive (HT: systolic arterial pressure &#x2265;160 mmHg) and 25 were non-hypertensive (Non-HT: systolic arterial pressure <160 mmHg). RESULTS: Mean SDMA was significantly lower after drug administration compared with before administration in both the HT and Non-HT groups. Moreover, we found that cardiac output (CO) increased in all dogs with CKD treated with amlodipine. Blood pressure measurements showed that the blood pressure decreased in both the HT and Non-HT groups. DISCUSSION: It is believed that the increase in CO due to amlodipine administration increases glomerular filtration rate, which may have led to a decrease in SDMA levels. Based on the rate of decrease in systolic arterial pressure, we considered that amlodipine might decrease blood pressure by a greater amount in patients with higher levels of hypertension. In this study, we showed that amlodipine administration improved SDMA in dogs with CKD regardless of whether they were hypertension. We also showed that amlodipine could be safely used to treat normotensive dogs.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40370820/